Nnamdi Njoku Sells 3,090 Shares of Omnicell (NASDAQ:OMCL) Stock

Omnicell, Inc. (NASDAQ:OMCL) EVP Nnamdi Njoku sold 3,090 shares of the business’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $43.22, for a total value of $133,549.80. Following the transaction, the executive vice president owned 154,785 shares of the company’s stock, valued at approximately $6,689,807.70. The trade was a 1.96% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Omnicell Trading Up 1.4%

OMCL traded up $0.60 during trading hours on Tuesday, reaching $43.82. 454,547 shares of the company’s stock traded hands, compared to its average volume of 625,723. The firm has a 50-day moving average price of $37.71 and a 200 day moving average price of $40.60. Omnicell, Inc. has a 52-week low of $26.84 and a 52-week high of $55.00. The company has a quick ratio of 1.29, a current ratio of 1.50 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $1.99 billion, a PE ratio of 99.59, a PEG ratio of 1.12 and a beta of 0.96.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Tuesday, April 28th. The company reported $0.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.33 by $0.22. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.The company had revenue of $309.88 million during the quarter, compared to analysts’ expectations of $304.02 million. During the same quarter in the previous year, the business earned $0.26 EPS. Omnicell’s revenue was up 14.9% compared to the same quarter last year. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. As a group, sell-side analysts predict that Omnicell, Inc. will post 1.31 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

OMCL has been the topic of a number of recent research reports. Zacks Research raised Omnicell from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 1st. Benchmark reaffirmed a “buy” rating on shares of Omnicell in a research note on Friday, March 13th. UBS Group set a $60.00 target price on shares of Omnicell and gave the stock a “buy” rating in a report on Friday, March 13th. Craig Hallum reissued a “buy” rating and set a $55.00 target price on shares of Omnicell in a research report on Wednesday, April 29th. Finally, Wells Fargo & Company boosted their price target on shares of Omnicell from $52.00 to $55.00 and gave the company an “overweight” rating in a report on Thursday, April 23rd. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $59.86.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Cerity Partners LLC raised its position in shares of Omnicell by 4.9% in the 4th quarter. Cerity Partners LLC now owns 7,613 shares of the company’s stock worth $345,000 after acquiring an additional 354 shares in the last quarter. SG Americas Securities LLC raised its position in shares of Omnicell by 6.6% in the 3rd quarter. SG Americas Securities LLC now owns 6,433 shares of the company’s stock worth $196,000 after acquiring an additional 401 shares in the last quarter. Thrivent Financial for Lutherans increased its position in Omnicell by 1.2% during the 2nd quarter. Thrivent Financial for Lutherans now owns 34,445 shares of the company’s stock valued at $1,013,000 after buying an additional 424 shares in the last quarter. Martin & Co. Inc. TN lifted its stake in shares of Omnicell by 0.4% during the third quarter. Martin & Co. Inc. TN now owns 121,720 shares of the company’s stock worth $3,706,000 after buying an additional 443 shares during the period. Finally, Legal & General Group Plc grew its holdings in shares of Omnicell by 0.3% during the third quarter. Legal & General Group Plc now owns 158,399 shares of the company’s stock valued at $4,823,000 after buying an additional 448 shares during the last quarter. 97.70% of the stock is owned by institutional investors.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.